136 related articles for article (PubMed ID: 19694583)
1. Preclinical assessment of an anti-EpCAM immunotoxin: locoregional delivery provides a safer alternative to systemic administration.
Brown J; Rasamoelisolo M; Spearman M; Bosc D; Cizeau J; Entwistle J; MacDonald GC
Cancer Biother Radiopharm; 2009 Aug; 24(4):477-87. PubMed ID: 19694583
[TBL] [Abstract][Full Text] [Related]
2. Novel PSCA targeting scFv-fusion proteins for diagnosis and immunotherapy of prostate cancer.
Kessler C; Pardo A; Tur MK; Gattenlöhner S; Fischer R; Kolberg K; Barth S
J Cancer Res Clin Oncol; 2017 Oct; 143(10):2025-2038. PubMed ID: 28667390
[TBL] [Abstract][Full Text] [Related]
3. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity.
Di Paolo C; Willuda J; Kubetzko S; Lauffer I; Tschudi D; Waibel R; Plückthun A; Stahel RA; Zangemeister-Wittke U
Clin Cancer Res; 2003 Jul; 9(7):2837-48. PubMed ID: 12855664
[TBL] [Abstract][Full Text] [Related]
4. A human recombinant autoantibody-based immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model.
Gattenlöhner S; Jörissen H; Huhn M; Vincent A; Beeson D; Tzartos S; Mamalaki A; Etschmann B; Muller-Hermelink HK; Koscielniak E; Barth S; Marx A
J Biomed Biotechnol; 2010; 2010():187621. PubMed ID: 20204062
[TBL] [Abstract][Full Text] [Related]
5. A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity.
Martin-Killias P; Stefan N; Rothschild S; Plückthun A; Zangemeister-Wittke U
Clin Cancer Res; 2011 Jan; 17(1):100-10. PubMed ID: 21075824
[TBL] [Abstract][Full Text] [Related]
6. Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer.
Cerise A; Bera TK; Liu X; Wei J; Pastan I
Clin Colorectal Cancer; 2019 Sep; 18(3):192-199.e1. PubMed ID: 31345777
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of VB6-845: an anti-EpCAM immunotoxin with reduced immunogenic potential.
Entwistle J; Brown JG; Chooniedass S; Cizeau J; MacDonald GC
Cancer Biother Radiopharm; 2012 Nov; 27(9):582-92. PubMed ID: 22856424
[TBL] [Abstract][Full Text] [Related]
8. Synergistic cytotoxicity of a prostate cancer-specific immunotoxin in combination with the BH3 mimetic ABT-737.
Noll T; Schultze-Seemann S; Kuckuck I; Michalska M; Wolf P
Cancer Immunol Immunother; 2018 Mar; 67(3):413-422. PubMed ID: 29188305
[TBL] [Abstract][Full Text] [Related]
9. Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies.
Flatmark K; Guldvik IJ; Svensson H; Fleten KG; Flørenes VA; Reed W; Giercksky KE; Fodstad Ø; Andersson Y
Int J Cancer; 2013 Sep; 133(6):1497-506. PubMed ID: 23494569
[TBL] [Abstract][Full Text] [Related]
10. Intraductal administration of transferrin receptor-targeted immunotoxin clears ductal carcinoma in situ in mouse models of breast cancer-a preclinical study.
Wang G; Kumar A; Ding W; Korangath P; Bera T; Wei J; Pai P; Gabrielson K; Pastan I; Sukumar S
Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2200200119. PubMed ID: 35675429
[TBL] [Abstract][Full Text] [Related]
11. Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice.
Bruell D; Bruns CJ; Yezhelyev M; Huhn M; Müller J; Ischenko I; Fischer R; Finnern R; Jauch KW; Barth S
Int J Mol Med; 2005 Feb; 15(2):305-13. PubMed ID: 15647848
[TBL] [Abstract][Full Text] [Related]
12. A novel immunotoxin recognising the epithelial glycoprotein-2 has potent antitumoural activity on chemotherapy-resistant lung cancer.
Zimmermann S; Wels W; Froesch BA; Gerstmayer B; Stahel RA; Zangemeister-Wittke U
Cancer Immunol Immunother; 1997 Mar; 44(1):1-9. PubMed ID: 9111578
[TBL] [Abstract][Full Text] [Related]
13. Improving the
Kaplan G; Mazor R; Lee F; Jang Y; Leshem Y; Pastan I
Mol Cancer Ther; 2018 Jul; 17(7):1486-1493. PubMed ID: 29695631
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin.
Reiter Y; Kreitman RJ; Brinkmann U; Pastan I
Int J Cancer; 1994 Jul; 58(1):142-9. PubMed ID: 8014011
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of compartmental administration of immunotoxin LMB-1 (B3-LysPE38) in a rat model of carcinomatous meningitis.
Bigner DD; Archer GE; McLendon RE; Friedman HS; Fuchs HE; Pai LH; Herndon JE; Pastan IH
Clin Cancer Res; 1995 Dec; 1(12):1545-55. PubMed ID: 9815955
[TBL] [Abstract][Full Text] [Related]
16. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys.
Kreitman RJ; Wang QC; FitzGerald DJ; Pastan I
Int J Cancer; 1999 Mar; 81(1):148-55. PubMed ID: 10077166
[TBL] [Abstract][Full Text] [Related]
17. Construction, expression, and characterization of a recombinant immunotoxin targeting EpCAM.
Lv M; Qiu F; Li T; Sun Y; Zhang C; Zhu P; Qi X; Wan J; Yang K; Zhang K
Mediators Inflamm; 2015; 2015():460264. PubMed ID: 25960617
[TBL] [Abstract][Full Text] [Related]
18. Monovalent immunotoxin containing truncated form of Pseudomonas exotoxin as potent antitumor agent.
Debinski W; Pastan I
Cancer Res; 1992 Oct; 52(19):5379-85. PubMed ID: 1394141
[TBL] [Abstract][Full Text] [Related]
19. Recombinant targeted toxin based on HER2-specific DARPin possesses a strong selective cytotoxic effect in vitro and a potent antitumor activity in vivo.
Sokolova E; Proshkina G; Kutova O; Shilova O; Ryabova A; Schulga A; Stremovskiy O; Zdobnova T; Balalaeva I; Deyev S
J Control Release; 2016 Jul; 233():48-56. PubMed ID: 27178808
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor activities of immunotoxins made of monoclonal antibody B3 and various forms of Pseudomonas exotoxin.
Pai LH; Batra JK; FitzGerald DJ; Willingham MC; Pastan I
Proc Natl Acad Sci U S A; 1991 Apr; 88(8):3358-62. PubMed ID: 2014255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]